IP Library Granted Patent US 10,507,226
Granted Patent B1
US 10,507,226 · App. 16/231,086 · Granted Dec 17, 2019

N-amino peptide beta-sheet mimics for the treatment of Alzheimer's disease

Inventor: Juan R. Del Valle (Tampa, FL)
Assignee: University of South Florida
A61K38/02A61P25/28C07K7/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,507,226
App. No.
16/231,086
Granted
Dec 17, 2019
Kind
B1
Abstract

Disclosed herein are compounds comprising short N-aminated peptides and compositions comprising the same. The disclosed compounds and compositions maybe used in methods of inhibiting amyloid-beta aggregation and treating Alzheimer's disease.

Claims (15)

1. A compound of formula (I),

or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are each independently selected from hydrogen or —NH 2 , and wherein at least one of R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 is —NH 2 .

2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein two of R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are —NH 2 .

3. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein R 1 and R 3 are —NH 2 .

4. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein R 1 and R 5 are —NH 2 .

5. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein R 2 and R 4 are —NH 2 .

6. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein R 2 and R 6 are —NH 2 .

7. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein R 3 and R 5 are —NH 2 .

8. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein R 4 and R 6 are —NH 2 .

9. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein three of R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are —NH 2 .

10. The compound of claim 9 , or a pharmaceutically acceptable salt thereof, wherein R 1 , R 3 and R 5 are —NH 2 .

11. The compound of claim 9 , or a pharmaceutically acceptable salt thereof, wherein R 2 , R 4 and R 6 are —NH 2 .

12. A pharmaceutical composition comprising an effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

13. A method of inhibiting amyloid-beta aggregation in a subject, comprising administering to the subject an effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 12 .

14. A method of treating a Alzheimer's disease in a subject, comprising administering to the subject a therapeutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 12 .

Assignments (2)
CONFIRMATORY LICENSE Recorded Feb 26, 2020
From: UNIVERSITY OF SOUTH FLORIDA
To: NATIONAL SCIENCE FOUNDATION
Reel/Frame 052020/0146 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 4, 2019
From: DEL VALLE, JUAN R.
To: UNIVERSITY OF SOUTH FLORIDA
Reel/Frame 048794/0039 →
Continuity (1)
Provisional Application 62665910 · May 2, 2018